Back
ESC Premium Access

First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers

Session: Antithrombotic Therapy Update
Topic: Anticoagulants
Speaker: Doctor V. Perera (Princeton, US)
Event: ESC Congress 2020

Congress Presentation

Add to my library

Like

About the speaker

Doctor Vidya Perera

Bayer, Princeton (United States of America)
1 follower

6 more presentations in this session

S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism

Speaker: Doctor P. Sansilvestri-Morel (Suresnes, FR)

Access
Abstract
Slides
Like
Thumbnail

Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys

Speaker: Doctor P. Wong (Princeton, US)

Access
Abstract
Slides
Like
Thumbnail

Orodispersible ticagrelor use in acute coronary syndrome patients: the Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation (TASTER) Study

Speaker: Professor G. Parodi (Sassari, IT)

Access
Abstract
Slides
Like
Thumbnail

Adherence to dual anti-platelet therapy after acute coronary syndrome and its impact on patient outcome

Speaker: Doctor P. Sulzgruber (Vienna, AT)

Access
Abstract
Slides
Like
Thumbnail

Benefit and risks of extended dual antiplatelet therapy beyond 1 year in high-risk patients after drug-eluting stent implantation

Speaker: Doctor H. Wang (Beijing, CN)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Antithrombotic Therapy Update

Speakers: Doctor V. Perera, Doctor P. Sansilvestri-Morel, Doctor P. Wong, Professor G. Parodi, Doctor P. Sulzgruber...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources